Fulgent Genetics (FLGT) Expected to Announce Quarterly Earnings on Thursday

Fulgent Genetics (NASDAQ:FLGT) is projected to post its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to announce earnings of ($0.46) per share and revenue of $94.00 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

Fulgent Genetics Stock Performance

Fulgent Genetics stock opened at $19.53 on Thursday. Fulgent Genetics has a fifty-two week low of $13.46 and a fifty-two week high of $31.04. The firm has a 50 day moving average price of $18.89 and a 200 day moving average price of $19.56. The company has a market capitalization of $554.67 million, a PE ratio of -8.17 and a beta of 0.89.

Insider Buying and Selling

In related news, insider Hanlin Gao sold 1,688 shares of Fulgent Genetics stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $17.89, for a total value of $30,198.32. Following the completion of the transaction, the insider owned 990,374 shares in the company, valued at approximately $17,717,790.86. The trade was a 0.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Jian Xie sold 2,146 shares of the company’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $17.89, for a total transaction of $38,391.94. Following the sale, the chief operating officer directly owned 367,605 shares in the company, valued at approximately $6,576,453.45. The trade was a 0.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 5,980 shares of company stock valued at $106,360 in the last 90 days. Company insiders own 36.18% of the company’s stock.

Institutional Trading of Fulgent Genetics

Hedge funds have recently modified their holdings of the stock. Kestra Advisory Services LLC acquired a new position in Fulgent Genetics during the 4th quarter worth $35,000. Raymond James Financial Inc. acquired a new stake in Fulgent Genetics in the 2nd quarter valued at about $49,000. Quantbot Technologies LP purchased a new position in shares of Fulgent Genetics in the 3rd quarter valued at about $61,000. Los Angeles Capital Management LLC purchased a new position in shares of Fulgent Genetics in the 4th quarter valued at about $218,000. Finally, Advisors Asset Management Inc. grew its position in shares of Fulgent Genetics by 2,205.7% during the fourth quarter. Advisors Asset Management Inc. now owns 8,485 shares of the company’s stock worth $223,000 after buying an additional 8,117 shares in the last quarter. 48.06% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have commented on FLGT. Weiss Ratings restated a “sell (e+)” rating on shares of Fulgent Genetics in a research note on Monday, July 6th. Wall Street Zen raised Fulgent Genetics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 30th. Finally, Piper Sandler reiterated a “neutral” rating and issued a $15.00 price objective (down from $30.00) on shares of Fulgent Genetics in a report on Tuesday, May 5th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $27.00.

About Fulgent Genetics

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.